InventisBio

Focus: InventisBio is a Shanghai-based biotech company focused on oncology and metabolic disease therapeutics, operating a diversified clinical pipeline across multiple disease areas.

Oncology Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About InventisBio

AI assessmentNot Hiring

No open roles listed right now. Follow InventisBio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

D-0120

Gout

Phase 1

Clinical Trials (1)

NCT03291782D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers

Phase 1

Help build intelligence for InventisBio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Active pipeline of 20 clinical programs across oncology and immunology, providing diverse therapeutic exposure
Multiple Phase 2 and Phase 3 programs (12 total programs) with near-term catalyst potential in psoriasis and breast cancer
Focus on underserved disease areas (psoriatic arthritis, lupus, gout) with emerging clinical validation

Watch Out For

Zero current job openings and no disclosed hiring activity signal organizational contraction or hiring freeze
Complete absence of financial data, publication record, and company metrics creates uncertainty around runway and scientific credibility
Early-stage pipeline (10 Phase 1, 9 Phase 2) with limited Phase 3 advancement suggests 5+ years to potential commercialization

Generated by Claude from InventisBio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

D-0120

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT04097405Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers

Phase 1

D-1553

Healthy Male

Phase 1

Clinical Trials (1)

NCT06105255A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553

Phase 1

D-2570

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT07270783Healthy Volunteer Study

Phase 1

D-0502

Healthy Female Volunteer

Phase 1

Clinical Trials (1)

NCT05226338Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects

Phase 1

D-0120 in combination with Allopurinol

Healthy

Phase 1

Clinical Trials (1)

NCT05360628Evaluation of PK and Safety of D-0120 and Allopurinol

Phase 1

D-2570

Healthy

Phase 1

Clinical Trials (1)

NCT07275775Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy Subjects

Phase 1

D-0316

Advanced Non Small Cell Lung Cancer

Phase 1

Clinical Trials (1)

NCT03452150D-0316 First Time in Patients Ascending Dose Study

Phase 1

D-0502

Breast Cancer

Phase 1

Clinical Trials (1)

NCT03471663A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Phase 1

[14C] D-2570 group

Mass Balance Study

Phase 1

Clinical Trials (1)

NCT07411742Mass Balance Study of [14C] D-2570

Phase 1

[14C]-D-0502

Mass Balance Recovery

Phase 1

Clinical Trials (1)

NCT05339633Study in Healthy Adult Female Subjects